Details of the Drug Reposition

General Information of This Drug (ID: DMYQFCN)

Drug Name
Anti-CD19-CAR T cells   DMYQFCN
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
B-cell lymphoma DISIH1YQ 2A86 Phase 1 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies